Approximately 25-30% of patients with non-small cell lung cancer (NSCLC) present with early stage disease and undergo surgery with curative intent. Despite complete tumor resection, many of these patients will develop systemic relapses with or without local relapses and will eventually die from the disease. Systemic relapses occur due to the presence of micro-metastatic disease at the time of surgery. In order to treat these micro-metastases in an early stage, adjuvant chemotherapy following complete tumor resection has been studied. A meta-analysis of early trials indicated a trend towards improved survival for adjuvant platinum-based chemotherapy (1) and led to re-evaluation of adjuvant chemotherapy in clinical trials on large patient populations (2-8). Several of these trials demonstrated that adjuvant chemotherapy improves survival (3-6). The survival benefit was then further confirmed in a meta-analysis that included all five cisplatin-based trials (9). Thus adjuvant chemotherapy has been established for patients with stages II and III. Here we summarize the current status of adjuvant chemotherapy in patients with completely resected NSCLC.
Meta-analysis of early trials
A meta-analysis of early adjuvant chemotherapy trials suggested an increase in the 5-year survival rate of absolute 5% by cisplatin-based chemotherapy but this difference did not reach statistical significance (1) . Based on this potential benefit, large randomized trials reevaluated the impact of adjuvant chemotherapy with platinum-based chemotherapy in patients with completely resected NSCLC (Table) (2) (3) (4) (5) (6) (7) (8) .
Recent adjuvant chemotherapy trials ALPI-EORTC study
The ALPI-EORTC study failed to demonstrate a significant survival benefit of adjuvant chemotherapy with mitomycin C, vindesine and cisplatin (2) . However, this protocol has been associated with enhanced toxicity and poor patient compliance and, therefore, is not in clinical use anymore. Patients who had undergone pneumonectomy were more likely to discontinue therapy due to toxicity (10).
Elderly patients did also benefit from acceptable toxicity (11) . Adjuvant chemotherapy was also considered to be cost effective (12) .
ANITA study
The ANITA trial (6) Other adjuvant chemotherapy trials Patients without ERCC1 expression in their tumors did benefit from adjuvant chemotherapy, whereas those with ERCC1 expression did not (16) . Similarly, lack of p27 expression predicted benefit from adjuvant chemotherapy 
Perspectives of adjuvant therapy

Integration of targeted therapies
The second strategy to improve outcome of adjuvant chemotherapy studies the integration of targeted therapies. 
